Keywords: Biogen Idec, Restructuring, Research Cardiokine, Lixivaptan, Hyponatremia

Biogen Idec to restructure, slashing jobs; abandons development of lixivaptan

Article | 04 November 2010

Print This

US biotech firm Biogen Idec (Nasdaq: BIIB), which recently report healthy third quarter 2010 results, also this week announced a round ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in